Analysts Set Agenus Inc. (NASDAQ:AGEN) Target Price at $14.00

Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $14.00.

Several analysts have recently commented on the company. Wall Street Zen raised Agenus from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 22nd. HC Wainwright raised Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Wednesday, June 4th. B. Riley restated a “buy” rating on shares of Agenus in a research note on Monday, April 21st. Finally, Robert W. Baird upped their target price on shares of Agenus from $4.00 to $6.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 4th.

Agenus Stock Performance

AGEN stock opened at $4.70 on Monday. The stock’s 50 day simple moving average is $3.32 and its 200 day simple moving average is $3.03. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $18.74. The company has a market cap of $128.86 million, a P/E ratio of -0.42 and a beta of 1.43.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million. Equities analysts predict that Agenus will post -12.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC raised its stake in shares of Agenus by 17.7% during the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 4,924 shares during the period. Apollon Wealth Management LLC boosted its stake in Agenus by 25.0% in the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 5,000 shares during the last quarter. Corton Capital Inc. bought a new position in shares of Agenus during the 4th quarter valued at approximately $36,000. Charles Schwab Investment Management Inc. increased its stake in shares of Agenus by 32.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 15,731 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Agenus during the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.